The life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, this week moved a step closer to commercialisation of one of its key research programmes, with the announcement that the clinical studies on its capsular food supplement to reduce cholesterol, had been completed by researchers at Reading University.
31 Jul 2015
Cholesterol results on track for Q3
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cholesterol results on track for Q3
OptiBiotix Health PLC (OPTI:LON) | 18.0 0 0.0% | Mkt Cap: 17.6m
- Published:
31 Jul 2015 -
Author:
Derren Nathan -
Pages:
6
The life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, this week moved a step closer to commercialisation of one of its key research programmes, with the announcement that the clinical studies on its capsular food supplement to reduce cholesterol, had been completed by researchers at Reading University.